Although there is a growing support for the protective factor of psychedelics to improve mental and physical health, these effects may differ across racial and ethnic groups. Race differences remain a critically understudied gap in psychedelic literature. Recent empirical research into Minority Diminished Psychedelic Returns suggests that Black Americans may gain little health benefits from psychedelic use. This study tests race differences in the association between Lifetime Classic Psychedelic Use and multiple indicators of cardio-metabolic health including cardiovascular disease, hypertension, and Body Mass Index. This project uses pooled data of Black and White adults respondents from the National Survey of Drug Use and Health (NSDUH) (2005 to 2019) (N = 421,477). The analysis includes a series of logistic and ordinary least square regression models conducted in Stata 18. Results demonstrate that Lifetime Psychedelic Use is associated with better cardio-metabolic health. However, regression models by race find that there is no association between LCPU and cardio metabolic health for Black people, while the positive associations remain significant for white people. Overall, results lend support for the MPDR theory.
AgunwambaAAKawachiIWilliamsDR, et al. (2017) Mental health, racial discrimination, and tobacco use differences across rural-urban California. The Journal of Rural Health33(2): 180–189.
2.
ArmstrongRA (2014) When to use the Bonferroni correction. Ophthalmic and Physiological Optics34(5): 502–508.
3.
AssariS (2017a) Combined racial and gender differences in the long-term predictive role of education on depressive symptoms and chronic medical conditions. Journal of Racial and Ethnic Health Disparities4(3): 385–396.
4.
AssariS (2017b) Social determinants of depression: The intersections of race, gender, and socioeconomic status. Brain Sciences7(12): 56.
5.
AssariS (2018a) Family income reduces risk of obesity for white but not black children. Children5(6): 73.
6.
AssariS (2018b) Life expectancy gain due to employment status depends on race, gender, education, and their intersections. Journal of Racial and Ethnic Health Disparities5(2): 375–386.
7.
AssariS (2018c) Race, intergenerational social mobility and stressful life events. Behavioral Sciences8(10): 86.
8.
AssariS (2020) Blacks’ diminished health returns of educational attainment: Health and retirement study. Journal of Medical Research and Innovation4(1): 1–11.
9.
AssariSChalianHBazarganM (2019) High education level protects European Americans but not African Americans against chronic obstructive pulmonary disease: National health interview survey. International Journal of Biomedical Engineering and Clinical Science5(2): 16.
10.
AssariSFarokhniaMMistryR (2019) Education attainment and alcohol binge drinking: Diminished returns of Hispanics in Los Angeles. Behavioral Sciences9(1): 9.
11.
AssariSLapeyrouseLMNeighborsHW (2018) Income and self-rated mental health: Diminished returns for high income black Americans. Behavioral Sciences8(5): 50.
12.
AssariSMistryR (2018) Educational attainment and smoking status in a national sample of American adults; evidence for the blacks’ diminished return. International Journal of Environmental Research and Public Health15(4): 63.
13.
AssariSPreiserBKellyM (2018) Education and income predict future emotional well-being of whites but not blacks: A ten-year cohort. Brain Sciences8(7): 1–22.
14.
BarnettBSParkerSEWeleffJ (2022) United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006–2020. International Journal of Drug Policy99: 103473.
15.
BarnettBSZieglerKDoblinR, et al. (2022) Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data. Journal of Psychopharmacology36(10): 1118–1128.
BowerKMThorpeRJRohdeC, et al. (2014) The intersection of neighborhood racial segregation, poverty, and urbanicity and its impact on food store availability in the United States. Preventive Medicine58(1): 33–39.
18.
BrewertonTDWangJBLafranceA, et al. (2022) MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. Journal of Psychiatric Research149: 128–135.
19.
BryanSAffulJCarrollM, et al. (2021) NHSR 158. National Health and Nutrition Examination Survey 2017–March 2020 Pre-pandemic Data Files. https://doi.org/10.15620/cdc:106273.
20.
Carhart-HarrisRLRosemanLHaijenE, et al. (2018) Psychedelics and the essential importance of context. Journal of Psychopharmacology32(7): 725–731.
21.
CarlinS (2020) MDMA therapy training for communities of color. MAPS Bulletin Research.
22.
ChingTHWDavisAKXinY, et al. (2023) Effects of psychedelic use on racial trauma symptoms and ethnic identity among Asians in North America. Journal of Psychoactive Drugs55(1): 19–29.
23.
ChingTHWWilliamsMTWangJB, et al. (2022) MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial. Journal of Psychopharmacology36(8): 974–986.
24.
CollinsPHCollinsPH (2015) Intersectionality’s definitional dilemmas. Annual Review of Public Health41: 1–20.
25.
DavisAKBarrettFSMayDG, et al. (2021) Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry78(5): 481–489.
26.
DavisAKXinYSepedaND, et al. (2021) Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color. Chronic Stress5: 247054702110356.
27.
DawJ (2017) Contribution of four comorbid conditions to racial/ethnic disparities in mortality risk. American Journal of Preventive Medicine52(1): S95–S102.
28.
DimsdaleJE (2008) Psychological stress and cardiovascular disease. Journal of the American College of Cardiology51(13): 1237–1246.
29.
dos SantosRGBousoJCAlcázar-CórcolesMÁ, et al. (2018) Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews. Expert Review of Clinical Pharmacology11(9): 889–902.
30.
FlanaganTWNicholsCD (2018) Psychedelics as anti-inflammatory agents. International Review of Psychiatry30(4): 363–375.
31.
FrühbeckGBakerJLBusettoL, et al. (2020) European association for the study of obesity position statement on the global COVID-19 pandemic. Obesity Facts13(2): 292–296.
32.
FrühbeckGYumukV (2014) Obesity: A gateway disease with a rising prevalence. Obesity Facts7(SUPPL. 2): 33–36.
33.
Garcia-RomeuABarrettFSCarbonaroTM, et al. (2021) Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. Journal of Psychopharmacology35(4): 353–361.
34.
GoodwinGMAaronsonSTAlvarezO, et al. (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine387(18): 1637–1648.
35.
GutinI (2018) In BMI we trust: Reframing the body mass index as a measure of health. Social Theory and Health16(3): 256–271.
36.
HahnRATrumanBIWilliamsDR (2018) Civil rights as determinants of public health and racial and ethnic health equity: Health care, education, employment, and housing in the United States. SSM - Population Health4: 17–24.
37.
HarderBMSumerauJE (2018) Understanding gender as a fundamental cause of health: Simultaneous linear relationships between gender, mental health, and physical health over time. Sociological Spectrum38(6): 387–405.
38.
HeJBundyJDGengS, et al. (2023) Social, behavioral, and metabolic risk factors and racial disparities in cardiovascular disease mortality in U.S. Adults. Annals of Internal Medicine176(9): 1200–1208.
39.
HendricksPSClarkCBJohnsonMW, et al. (2014) Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. Journal of Psychopharmacology28(1): 62–66.
40.
HendricksPSCrawfordMSCropseyKL, et al. (2018) The relationships of classic psychedelic use with criminal behavior in the United States adult population. Journal of Psychopharmacology32(1): 37–48.
41.
HendricksPSThorneCBClarkCB, et al. (2015) Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology29(3): 280–288.
42.
HartogsohnI (2016). Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology30(12): 1259–1267.
43.
HartogsohnI (2022). Modalities of the psychedelic experience: Microclimates of set and setting in hallucinogen research and culture. Transcultural Psychiatry0(0): 1–13. 10.1177/13634615221100385
44.
JonesGMNockMK (2022). Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality. Scientific Reports37(1): 61–69.
45.
JonesGM (2023) Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes. Journal of Psychopharmacology37(1): 61–69.
46.
JonesGMNockMK (2022a) MDMA/Ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. Journal of Psychopharmacology36(1): 46–56.
47.
JonesGMNockMK (2022b) Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality. Scientific Reports12(1). https://doi.org/10.1038/s41598-022-18645-3.
KwateNOA (2008) Fried chicken and fresh apples: Racial segregation as a fundamental cause of fast food density in black neighborhoods. Health & Place14(1): 32–44.
50.
KyalwaziANLoccohECBrewerLC, et al. (2022) Disparities in cardiovascular mortality between Black and White adults in the United States, 1999 to 2019. Circulation146(3): 211–228.
51.
LamkinM (2021) Prescription psychedelics: The road from FDA approval to clinical practice. The American Journal of Medicine135(1): 15–16.
52.
LinkBGPhelanJC (1995) Social conditions as fundamental causes of disease author. Journal of Health and Social Behavior35: 80–94.
LongJSFreeseJ (2014) Regression models for categorical dependent variables using stata, 3rd ed.College Station, TX: Stata Press.
55.
MarksM (2023) The varieties of psychedelic law. Neuropharmacology226: 109399.
56.
MellnerCDahlenMSimonssonO (2022) Association between lifetime classic psychedelic use and sick leave in a population-based sample. International Journal of Environmental Research and Public Health19(18): 11353.
57.
MichaelsTIPurdonJCollinsA, et al. (2018) Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. BMC Psychiatry18(1): 45.
58.
MithoeferMCFeducciaAAJeromeL, et al. (2019) MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology236(9): 2735–2745.
59.
MurphySLKochanekKDXuJ, et al. (2020) Mortality in the United States, 2020. https://doi.org/https://dx.doi.org/10.15620/cdc:112079.
60.
Neitzke-SpruillL (2019) Race as a component of set and setting: How experiences of race can influence psychedelic experiences. Journal of Psychedelic Studies4(1): 51–60.
61.
NicholsCD (2009) Serotonin 5- receptor function as a contributing factor to both neuropsychiatric and cardiovascular diseases. Cardiovascular Psychiatry and Neurology2009: 1–8.
62.
NIH (2021) Marijuana use at historic high among college-aged adults in 2020.
63.
OberfichtnerMTauchmannH (2021) Stacked linear regression analysis to facilitate testing of hypotheses across OLS regressions. The Stata Journal: Promoting Communications on Statistics and Stata21(2): 411–429.
64.
OlloveM (2022, July 15) More States May Legalize Psychedelic Mushrooms. Stateline.
65.
OlshanskySJAntonucciTBerkmanL, et al. (2012) Differences in life expectancy due to race and educational differences are widening, and many may not catch up. Health Affairs31(8): 1803–1813.
66.
OngADWilliamsDR (2019) Lifetime discrimination, global sleep quality, and inflammation burden in a multiethnic sample of middle-aged adults. Cultural Diversity and Ethnic Minority Psychology25(1): 82–90.
67.
OngADWilliamsDRNwizuU, et al. (2017) Everyday unfair treatment and multisystem biological dysregulation in African American adults. Cultural Diversity and Ethnic Minority Psychology23(1): 27–35.
68.
PennADorsenCGHopeS, et al. (2021) Psychedelic-assisted therapy: Emerging treatments in mental health disorders. AJN, American Journal of Nursing121(6): 34–40.
69.
PhelanJCLinkBG (2015) Is racism a fundamental cause of inequalities in health?Annual Review of Sociology41: 311–330.
70.
PeckR (2021) The psychedelic renaissance: A convergence of Indigenous knowledge and science [Portland State University]. https://doi.org/10.15760/honors.1171.
71.
RosemanLNuttDJCarhart-HarrisRL (2018) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology8(JAN), 1–10.
72.
SchwandtHCurrieJBärM, et al. (2021) Inequality in mortality between Black and White Americans by age, place, and cause, and in comparison to Europe, 1990-2018. https://doi.org/10.3386/w29203.
73.
SextonJDCrawfordMSSweatNW, et al. (2019) Prevalence and epidemiological associates of novel psychedelic use in the United States adult population. Journal of Psychopharmacology33(9): 1058–1067.
74.
SherryA (2022, September 13) Thousands of moms are microdosing with mushrooms to ease the stress of parenting. NPR.
75.
ShippeeTPSchaferMHFeuilleM (2012) Beyond the barriers: Racial discrimination and use of complementary and alternative medicine among Black Americans. Social Science & Medicine74(8): 1155–1162.
76.
SimonssonOHendricksPSCarhart-HarrisR, et al. (2021) Association between lifetime classic psychedelic use and hypertension in the past year. Hypertension77(5): 1510–1516.
77.
SimonssonOHendricksPSChambersR, et al. (2022) Classic psychedelics, health behavior, and physical health. Therapeutic Advances in Psychopharmacology12: 204512532211353.
78.
SimonssonOOsikaWCarhart-HarrisR, et al. (2021) Associations between lifetime classic psychedelic use and cardiometabolic diseases. Scientific Reports11(1): 10–14.
79.
SimonssonOSextonJDHendricksPS (2021) Associations between lifetime classic psychedelic use and markers of physical health. Journal of Psychopharmacology35(4): 447–452.
80.
SinhaRJastreboffAM (2013) Stress as a common risk factor for obesity and addiction. Biological Psychiatry73(9): 827–835.
81.
SlopenNLewisTTWilliamsDR (2016) Discrimination and sleep: A systematic review. Sleep Medicine18: 88–95.
82.
SmithDTFaberSCBuchananNCT, et al. (2022) The need for psychedelic-assisted therapy in the Black community and the burdens of its provision. Frontiers in Psychiatry12(Jan), 1–15.
83.
SudanoJJPerzynskiAWongDW, et al. (2013) Neighborhood racial residential segregation and changes in health or death among older adults. Health & Place19(1): 80–88.
84.
ThompsonDEdelsbergJColditzGA, et al. (1999) Lifetime health and economic consequences of obesity. Archives of Internal Medicine159(18): 2177.
85.
ThrulJGarcia-RomeuA (2021) Whitewashing psychedelics: Racial equity in the emerging field of psychedelic-assisted mental health research and treatment. Drugs: Education, Prevention and Policy28(3): 211–214.
86.
TogiokaBMDuvivierDYoungE (2022) Diversity and Discrimination In Healthcare. Treasure Island, FL: StatPearls.
87.
Van DykeMEBaumhoferNKISlopenN, et al. (2020) Pervasive discrimination and allostatic load in African American and white adults. Psychosomatic Medicine82(3): 316–323.
88.
ViñaS (2022, August 6) The harmful relationship between classic psychedelic use and religion on mental health. In: American Sociological Association 117th Annual Meeting: Bureaucracies of Displacement.
89.
ViñaSMStephensAL (2023a) Minorities’ diminished psychedelic returns. Drug Science, Policy and Law9, 1–19.
90.
ViñaSMStephensAL (2023b) Psychedelics and workplace harm. Frontiers in Psychiatry14(June), 1–9.
91.
WalshZHendricksPSSmithS, et al. (2016) Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use. Journal of Psychopharmacology30(7): 601–607.
92.
WilliamsDRYuYJacksonJS, et al. (1997). Racial differences in physical and mental health: Socio-economic status, stress and discrimination. Journal of Health Psychology2(3): 335–351.
93.
WilliamsDRCollinsC (2001) Racial residential segregation project: A fundamental cause of racial disparities in health. Public Health Reports116(5): 404–416.
94.
WilliamsDRLawrenceJADavisBA (2019) The annual review of public health is online at. South Africa Annual Review of Public Health40: 105–125.
95.
WilliamsMTDavisAKXinY, et al. (2021) People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs: Education, Prevention and Policy28(3): 215–226.
96.
YadenDBBerghellaAPRegierPS, et al. (2021) Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. International Journal of Drug Policy98: 103380.
97.
YauYHCPotenzaMN (2014) Stress and eating behaviors. Minerva Endocrinol 38(3): 255–267.
98.
ZeifmanRJSinghalNBreslowL, et al. (2021) On the relationship between classic psychedelics and suicidality: A systematic review. ACS Pharmacology and Translational Science4(2): 436–451.
99.
Zeki Al HazzouriAHaanMNGaleaS, et al. (2011) Life-course exposure to early socioeconomic environment, education in relation to late-life cognitive function among older Mexicans and Mexican Americans. Journal of Aging and Health23(7): 1027–1049.
100.
ZenkSNSchulzAJIsraelBA, et al. (2005) Neighborhood racial composition, neighborhood poverty, and the spatial accessibility of supermarkets in metropolitan Detroit. American Journal of Public Health95(4): 660–667.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
